Maryland's biopharmaceutical industry showcases a vibrant ecosystem focused on innovative drug development, spanning sectors from vaccines to chronic disease treatments. Companies here range from established giants to nimble startups, each contributing unique products targeting serious health challenges. Recent years have seen a surge in investment and collaboration, facilitating rapid advancements in therapies driven by rigorous research and cutting-edge technologies. As the demand for personalized medicine continues to rise, Maryland stands out as a promising hub for biopharmaceutical innovation, attracting talent and funding necessary to push the boundaries of healthcare solutions.

This listing features 19 biopharmaceutical companies based in Maryland, varying significantly in size and specialization. From the well-established MedImmune with thousands of employees to small entities like Rise Therapeutics, formed just a few years ago, these companies are committed to diverse therapeutic areas. With foundations ranging from 1957 to 2020, their research efforts encompass oncology, immunology, and gene therapy, reflecting both maturation and fresh innovation in the state’s biopharmaceutical scene.

Continue reading to discover the top biopharmaceutical companies in Maryland.

Top 19 Biopharmaceuticals Companies in Maryland

1. MedImmune

• Website: medimmune.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 78%, United Kingdom (UK) 18%, Other 4%
• Latest funding: $15.6B, April 2007
• Founded year: 1987
• Headcount: 1001-5000
• LinkedIn: medimmune

MedImmune, founded in 1987 and based in Gaithersburg, Maryland, is a biopharmaceutical company that specializes in the research and development of innovative medicines. As a subsidiary of AstraZeneca, MedImmune plays a crucial role in advancing treatments across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases. The company is dedicated to improving health outcomes through its robust pipeline of products and a strong commitment to sustainability. With a workforce of approximately 960 employees, MedImmune is actively involved in clinical innovation and the development of next-generation therapeutics, contributing to the broader mission of AstraZeneca to transform healthcare. The company has received substantial funding, with a notable amount of $15.6 billion reported in 2007, which underscores its potential for growth and innovation in the biopharmaceutical field.

2. Rise Therapeutics

• Website: risetherapeutics.com
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), October 2024
• Founded year: 2017
• Headcount: 1-10
• LinkedIn: rise-therapeutics

Rise Therapeutics, founded in 2017 and based in Rockville, Maryland, is a biotechnology company dedicated to developing targeted immunological-based biologics. The company specializes in creating innovative oral immunotherapeutics aimed at treating chronic diseases such as autoimmunity, cancer, and infections. Rise Therapeutics leverages cutting-edge research in synthetic biology and microbiome science to advance its drug development efforts. Their proprietary Tripartite X (TPX) drug delivery platform enables the oral delivery of biologic therapies, which is a significant innovation in the field. The company has a strong emphasis on research and development, supported by their clinical GMP manufacturing capabilities. Recently, Rise Therapeutics received FDA clearance for its IND application to initiate a Phase 1 clinical study for its candidate R-2487, targeting rheumatoid arthritis. This milestone reflects their active engagement in the biopharmaceutical industry and their potential to bring new therapies to market.

3. TopAlliance Biosciences Inc

• Website: topalliancebio.com
• Ownership type: Private Equity
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 78%, Singapore 13%, China 9%
• Latest funding: January 2014
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: topalliance-biosciences-inc

TopAlliance Biosciences Inc, founded in 2013 and based in Rockville, Maryland, is a biopharmaceutical company dedicated to the discovery and development of innovative drugs, with a strong emphasis on oncology. The company operates through advanced research and development processes and has established manufacturing capabilities to support its drug development efforts. Their flagship therapy, LOQTORZI™ (also known as Toripalimab), is an anti-PD-1 monoclonal antibody that has shown promising clinical results and has been approved by the FDA for use in treating recurrent or metastatic nasopharyngeal carcinoma. TopAlliance is committed to addressing unmet medical needs and improving patient outcomes through its innovative therapies. The company is part of a global network, with operations in the United States, Singapore, and China, and is backed by its parent company, Shanghai Junshi Biosciences, which has a notable history in the biopharmaceutical field.

4. Salubris Biotherapeutics

• Website: salubrisbio.com
• Ownership type: Corporate
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 83%, Vietnam 9%, China 9%
• Latest funding: Series A, $35.0M, April 2024
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: salubris-biotherapeutics

Salubris Biotherapeutics, Inc. is a biotechnology firm based in Gaithersburg, Maryland, established in 2016. The company specializes in the development of innovative biologics aimed at treating complicated diseases, with a strong emphasis on cardiovascular conditions and cancer. Salubris is notable for being the first company globally to bring a bispecific antibody into clinical trials for a cardiovascular indication. Their product pipeline includes JK06, a targeted antibody-drug conjugate (ADC) for solid tumors, and JK07, an antibody fusion protein for heart failure. Salubris has recently raised $35 million in Series A funding, which will support their ongoing clinical trials and research initiatives. The company operates with a dedicated team of industry experts, reflecting a commitment to advancing therapeutic options for patients facing significant health challenges.

5. OncoC4, Inc.

• Website: oncoc4.com
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 97%, Australia 3%
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: oncoc4

OncoC4, Inc. is a biopharmaceutical company based in Rockville, Maryland, founded in 2020. The company specializes in developing innovative therapies for cancer, particularly through the targeting of immune checkpoints. Their mission is to create first-in-class and best-in-class medicines that enhance the immune response against various cancers. OncoC4's pipeline includes several promising programs, such as their CTLA-4 antibody therapy, which is currently in clinical trials in partnership with BioNTech. They also focus on Siglec and CD24 platforms, which aim to address the challenges of treating solid and hematologic malignancies. With a dedicated team of experts and a commitment to advancing cancer treatment, OncoC4 is positioned to make a significant impact in the biopharmaceutical industry.

6. Georgiamune Inc.

• Website: georgiamune.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $75.0M, August 2023
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: georgiamune

Georgiamune Inc., founded in 2014 and based in Gaithersburg, Maryland, is a biopharmaceutical company dedicated to the development of innovative immunotherapeutics aimed at treating cancer and autoimmune diseases. The company specializes in reprogramming immune responses through a pipeline of first-in-class drugs designed to target significant unmet medical needs. Their approach involves regulating immune signaling pathways to restore immune balance, which is crucial for effective treatment. Georgiamune's portfolio includes several promising candidates, such as GIM-122, a dual-functioning antibody, and GIM-531, a Treg inhibitor, among others. The company has recently secured $75 million in Series A funding, reflecting investor confidence in their potential to advance immunotherapy solutions. With a team of experienced scientists and clinicians, Georgiamune is positioned to make meaningful contributions to the biopharmaceutical industry.

7. VERALOX Therapeutics

• Website: veralox.com
• Ownership type: Venture Capital
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $24.0M, June 2023
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: veralox-therapeutics

VERALOX Therapeutics, founded in 2018 and based in Frederick, Maryland, is a biotechnology firm dedicated to developing innovative treatments for life-threatening immuno-inflammatory diseases. The company is currently advancing its lead candidate, VLX-1005, which targets heparin-induced thrombocytopenia (HIT). This first-in-class small molecule inhibitor has garnered attention for its novel mechanism of action and has received both FDA and EMA orphan drug designations, highlighting its potential to fill a critical gap in treatment options. With a small team of around 18 employees, VERALOX is agile and focused, engaging in research and development to tackle significant medical challenges. The company recently raised $24 million in funding, reflecting strong investor interest in their mission and pipeline.

8. Neuraly Inc.

• Website: neuralymed.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $36.0M, July 2018
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: neuraly-inc

Neuraly Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, founded in 2016. The company is dedicated to developing revolutionary treatments for neurodegenerative diseases, including Parkinson's and Alzheimer's. Neuraly leverages cutting-edge scientific research to create therapies that aim to modify the disease process rather than merely alleviate symptoms. Their lead product, NLY01, is a long-acting GLP-1 receptor agonist that targets glial cell activation, a critical factor in neuroinflammation and neuronal cell death. Neuraly is currently advancing NLY01 through Phase 2 clinical trials, demonstrating their commitment to bringing innovative solutions to market. The company operates under the umbrella of D&D Pharmatech, which supports its development efforts through strategic funding and expertise. Neuraly has raised $36 million in Series A funding, underscoring investor confidence in their approach and potential impact in the biopharmaceutical industry.

9. BioFactura, Inc.

• Website: biofactura.com
• Ownership type: Corporate
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $1.0M, July 2020
• Founded year: 2003
• Headcount: 11-50
• LinkedIn: biofactura-inc-

BioFactura, Inc., founded in 2003 and based in Frederick, Maryland, is a biopharmaceutical company dedicated to the development and manufacturing of high-value biosimilars and biodefense medical countermeasures. The company aims to meet unmet medical needs through innovative drug development, particularly focusing on therapeutics for smallpox and Marburg virus. BioFactura utilizes its proprietary StableFast™ Biomanufacturing Platform, which enhances the efficiency and quality of biopharmaceutical production. The company has established partnerships with government agencies and healthcare organizations, reflecting its role in addressing biological threats. BioFactura has received various grants and contracts, including a recent $16 million contract option for its smallpox therapeutic, showcasing its active involvement in the biopharmaceutical industry and its commitment to advancing life-saving medicines.

10. Immunomic Therapeutics, Inc.

• Website: immunomix.com
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $3.0M, April 2024
• Founded year: 2005
• Headcount: 11-50
• LinkedIn: immunomic-therapeutics-inc-

Immunomic Therapeutics, Inc. is a biotechnology firm based in Rockville, Maryland, founded in 2005. The company specializes in the development of immunotherapies and vaccines, primarily targeting critical medical needs in oncology. Utilizing its proprietary UNITE® platform, Immunomic Therapeutics aims to create vaccines that generate robust immune responses against various cancers. Their pipeline includes several investigational products, such as ITI-1000 and ITI-1001, both targeting glioblastoma multiforme, and ITI-3000 for Merkel cell carcinoma. The company collaborates with notable research institutions, including the University of Florida and Dana Farber Cancer Institute, to advance its clinical trials. Recently, they secured $3 million in funding, reflecting confidence in their innovative approach to cancer treatment and the potential of their technology.

11. Integrated BioTherapeutics, Inc.

• Website: integratedbiotherapeutics.com
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Latest funding: $1.0M, May 2023
• Founded year: 2005
• Headcount: 11-50
• LinkedIn: integrated-biotherapeutics-inc.

Integrated BioTherapeutics, Inc. (IBT) is a biotechnology firm based in Rockville, Maryland, established in 2005. The company specializes in the development of vaccines and antibody therapeutics aimed at combating infectious diseases. IBT's research is particularly focused on addressing the challenges posed by emerging viral threats and antibiotic-resistant bacteria. Their product pipeline includes innovative candidates such as a vaccine for Staphylococcus aureus, which is expected to enter clinical trials in 2024, and a range of monoclonal antibodies targeting various infectious agents, including Ebola and Marburg viruses. IBT collaborates with government agencies and academic institutions, enhancing their research capabilities and expanding their impact in public health. The company has successfully secured over $120 million in non-dilutive funding since its inception, reflecting strong support for its mission and projects.

12. Revolo Biotherapeutics

• Website: revolobio.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United Kingdom (UK) 62%, United States (USA) 38%
• Latest funding: Series B, $52.0M, September 2020
• Founded year: 2011
• Headcount: 11-50
• LinkedIn: immune-regulation-limited

Revolo Biotherapeutics, founded in 2011 and based in Gaithersburg, Maryland, is a biotechnology firm dedicated to developing innovative therapies for autoimmune and allergic diseases. The company is pioneering a unique approach to treatment by aiming to reset the immune system, which could lead to long-lasting disease remission. Their lead candidates, '1104 and '1805, are currently advancing through clinical trials, with '1104 targeting eosinophilic esophagitis and allergic diseases, while '1805 is being developed for rheumatoid arthritis and ulcerative colitis. Revolo's commitment to minimizing side effects associated with conventional therapies positions it as a forward-thinking player in the biopharmaceutical sector. The company has successfully raised over $52 million in its latest funding round, reflecting strong investor interest in its innovative pipeline and potential impact on patient care.

13. SciNeuro Pharmaceuticals

• Website: scineuro.com
• Ownership type: Private Equity
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 62%, China 38%
• Latest funding: Series A, $100.0M, December 2020
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: scineuro-pharmaceuticals

SciNeuro Pharmaceuticals, based in Rockville, Maryland, is a biotechnology firm established in 2020. The company is dedicated to creating innovative therapeutics aimed at treating central nervous system diseases. With a team of experienced scientists and industry leaders, SciNeuro is focused on translating scientific insights into transformative medicines. Their research is underpinned by a strong understanding of disease biology and the latest advancements in human genetics and pharmacology. The company has developed a pipeline of investigational therapies that target critical biological processes associated with various CNS conditions. In December 2020, SciNeuro raised $100 million in Series A funding, which has enabled them to accelerate their research and development efforts. Their commitment to addressing the challenges in CNS treatment positions them as a relevant player in the biopharmaceutical industry.

14. Deka Biosciences, Inc

• Website: dekabiosciences.com
• Ownership type: Venture Capital
• Headquarters: Germantown, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $29.9M, December 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: deka-biosciences-inc

Deka Biosciences, Inc., based in Germantown, Maryland, is a biotechnology firm established in 2018. The company specializes in personalized immunotherapy treatments aimed at addressing cancer and inflammatory diseases. Utilizing their proprietary Diakine™ platform, Deka develops therapies that leverage the immune system's capabilities to combat these conditions. Their approach is notable for combining various cytokines to create targeted treatments that can adapt to individual patient needs. Deka's primary customers include healthcare providers and patients seeking effective therapeutic options. Recently, the company secured approximately $29.9 million in funding, reflecting strong investor interest and support for their innovative strategies in the biopharmaceutical space. With a dedicated team of professionals, Deka is positioned to make significant contributions to the field of immunotherapy.

15. AbelZeta

• Website: abelzeta.com
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 57%, China 43%
• Founded year: 2009
• Headcount: 201-500
• LinkedIn: cellular-biomedicine-group

AbelZeta Pharma, founded in 2009 and based in Rockville, Maryland, is a private biopharmaceutical company dedicated to the development of innovative T cell-based therapeutics aimed at treating cancer and immunological diseases. The company has a focused pipeline that includes therapies for hematological cancers and solid tumors, utilizing advanced techniques such as Chimeric Antigen Receptor T-cell (CAR-T) and Tumor Infiltrating Lymphocytes (TIL) therapies. AbelZeta has made significant strides since treating its first oncology patient in 2015, including the licensing of two CD20-directed autologous CAR-T therapies to Janssen Biotech in 2023. Their strategy involves leveraging partnerships with multinational pharmaceutical companies to enhance global patient access to their therapies. AbelZeta's commitment to research and development is evident in their active participation in clinical trials and their focus on optimizing therapeutic candidates to maximize efficacy while minimizing toxicity.

16. Rapafusyn Pharmaceuticals

• Website: rapafusyn.com
• Ownership type: Venture Capital
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $28.0M, June 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: rapafusyn-pharmaceuticals

Rapafusyn Pharmaceuticals, founded in 2015 and based in Baltimore, Maryland, is a biotechnology firm dedicated to advancing drug discovery and development. The company specializes in creating non-degrading molecular glues, known as RapaGlues™, which are designed to tackle difficult drug targets. Their platform utilizes large DNA-encoded libraries and arrayed libraries to generate novel chemical starting points for hard-to-drug targets, enhancing the potential for effective therapeutic agents. Recently, Rapafusyn secured $28 million in Series A funding, which will bolster their capabilities and support the development of their innovative drug candidates. The company primarily serves pharmaceutical companies and research institutions, aiming to improve patient outcomes across various medical fields.

17. American Gene Technologies International Inc.

• Website: americangene.com
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, April 2022
• Founded year: 2007
• Headcount: 11-50
• LinkedIn: american-gene-technologies-international-inc

American Gene Technologies International Inc. (AGT), founded in 2007 and based in Rockville, Maryland, is a biotechnology firm dedicated to advancing gene therapy and innovative treatments for infectious diseases, cancers, and genetic disorders. The company is particularly focused on developing clinical solutions that provide long-term cures, with notable programs targeting HIV and Phenylketonuria (PKU). AGT has established a robust pipeline that includes therapies currently in clinical trials, demonstrating their commitment to addressing significant health challenges. Their operations involve extensive research and collaboration with medical experts, which enhances their credibility in the biopharmaceutical industry. AGT occupies a specialized laboratory space that supports their research and development efforts, and they have successfully navigated funding rounds to support their initiatives, including a Series D funding round in 2022. This financial backing, combined with their innovative approach, positions AGT as a relevant entity in the biopharmaceutical sector.

18. Leadiant Biosciences, inc.

• Website: leadiant.com
• Ownership type: Private
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 79%, Italy 21%
• Founded year: 1957
• Headcount: 51-200
• LinkedIn: sigma-tau-pharmaceuticals-inc-

Leadiant Biosciences, Inc. is a private pharmaceutical company based in Gaithersburg, Maryland, established in 1957. The company specializes in the research, development, and distribution of therapies aimed at rare diseases. With a workforce of approximately 53 employees, Leadiant is dedicated to addressing unique health challenges faced by patients. Their product portfolio includes notable therapies such as Abelcet® (amphotericin B lipid complex injection), Carnitor® (levocarnitine), Cystaran® (cysteamine ophthalmic solution), and Matulane® (procarbazine hydrochloride). Leadiant emphasizes collaboration with healthcare professionals and researchers to enhance treatment options and improve patient outcomes. Their focus on rare diseases highlights their commitment to filling gaps in treatment availability, ensuring that patients receive the necessary support and resources throughout their healthcare journey.

19. Remedy Plan Therapeutics

• Website: remedyplan.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $19.1M, August 2023
• Founded year: 2011
• Headcount: 1-10
• LinkedIn: remedy-plan

Remedy Plan Therapeutics, founded in 2011 and based in Gaithersburg, Maryland, is a biotechnology company dedicated to developing innovative therapeutics that target NAMPT inhibition. This enzyme plays a crucial role in cellular metabolism, and its dysregulation is linked to over 20 diseases, including various cancers, autoimmune disorders, and obesity. Remedy Plan employs a proprietary drug screening platform to discover and optimize new drugs, with a focus on their clinical candidate RPT1G, which aims to mitigate the on-target toxicity that has hindered previous NAMPT inhibitors. The company has a small team of experienced scientists and has recently raised approximately $19 million in funding, reflecting its active engagement in the biopharmaceutical industry. Their work is particularly relevant to healthcare providers and pharmaceutical companies seeking effective treatment solutions.

Biopharmaceuticals Insights: Key Companies in Maryland

Want to Find More Biopharmaceuticals Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!